title: Anti-tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis.
authors: Tokyo Medical and Dental University Graduate School of Health Sciences, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan. tetsuo.kubota.mtec@tmd.ac.jp
authors: Tetsuo
authors: T
authors: Kubota
authors: Tokiko
authors: T
authors: Nii
authors: Toshihiro
authors: T
authors: Nanki
authors: Hitoshi
authors: H
authors: Kohsaka
authors: Masayoshi
authors: M
authors: Harigai
authors: Yukiko
authors: Y
authors: Komano
authors: Takahiko
authors: T
authors: Sugihara
authors: Yoshinori
authors: Y
authors: Nonomura
authors: Wataru
authors: W
authors: Hirose
authors: Kenji
authors: K
authors: Nagasaka
authors: Tetsushi
authors: T
authors: Sakurai
authors: Nobuyuki
authors: N
authors: Miyasaka
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000917:Antibody Formation / Q000276:immunology*; D018501:Antirheumatic Agents / Q000276:immunology* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000276:immunology*; D000068800:Etanercept; D006801:Humans; D007121:Immunocompetence / Q000187:drug effects / Q000276:immunology*; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D007252:Influenza Vaccines / Q000276:immunology*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D007252:Influenza Vaccines; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept